DSIJ Mindshare

Lupin gets USFDA approval for Paraxetin tablets

Lupin Limited has informed The Bombay Stock Exchange Ltd and National Stock Exchange Ltd. on January 23, 2017, that it has received final approval from the US Food and Drug Administration.
  
The company has received USFDA approval for Paraxetin Extended Release Tablets USP, 12.5 mg, 25 mg, which is a generic version of Apotex Technologies, Inc’s Paxil CR® tablets, 12.5 mg,  25 mg and 37.5 mg.
 
Lupin Ltd is a pharmaceuticals major based in Mumbai, having current market capitalisation of Rs 66,149.44 crore. The stock has is up today and has made intra-day high at Rs 1490, up by more than 1.50 per cent on Monday morning.

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

IPO Analysis29-Mar, 2024

Expert Speak29-Mar, 2024

Mindshare29-Mar, 2024

Multibaggers28-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR